Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 7.3% – Should You Buy?

Lyell Immunopharma, Inc. (NASDAQ:LYEL)’s stock price rose 7.3% during mid-day trading on Friday . The company traded as high as $24.84 and last traded at $24.5970. Approximately 44,997 shares changed hands during trading, a decline of 54% from the average daily volume of 98,160 shares. The stock had previously closed at $22.93.

Wall Street Analyst Weigh In

LYEL has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Wednesday, October 8th. HC Wainwright raised shares of Lyell Immunopharma from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $20.00 to $45.00 in a report on Tuesday, December 9th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Lyell Immunopharma has a consensus rating of “Hold” and a consensus price target of $45.00.

Lyell Immunopharma Stock Performance

The company has a market capitalization of $504.66 million, a P/E ratio of -1.03 and a beta of -0.13. The stock has a fifty day moving average of $26.42 and a 200 day moving average of $17.79.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($2.13) EPS for the quarter, topping analysts’ consensus estimates of ($2.81) by $0.68. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%.The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.01 million. Research analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors and hedge funds have recently bought and sold shares of LYEL. ARCH Venture Management LLC grew its holdings in Lyell Immunopharma by 51.5% during the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock valued at $44,807,000 after buying an additional 938,438 shares in the last quarter. Vanguard Group Inc. grew its stake in Lyell Immunopharma by 76.0% during the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after acquiring an additional 336,378 shares in the last quarter. Acadian Asset Management LLC grew its stake in Lyell Immunopharma by 204.2% during the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after acquiring an additional 443,614 shares in the last quarter. Foresite Capital Management V LLC increased its holdings in Lyell Immunopharma by 17.3% in the 3rd quarter. Foresite Capital Management V LLC now owns 477,078 shares of the company’s stock valued at $7,748,000 after acquiring an additional 70,426 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Lyell Immunopharma by 773.5% in the 1st quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after purchasing an additional 154,327 shares in the last quarter. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.